VOTE NO. AWAIT "BEST & FINAL" DECLARATION, page-193

A very appropriate strategy rustys33.

ResAppDx is where the money is going to be and, according to the Expert Report, will only take another $1 million to fully develop it (then the marketing costs). That's a small CR at current price. They must have produced that figure after discussions with RAP and, remember, RAP saw the draft Report.

As I have pointed out previously (see link below), when the Covid data is 'twigged' we will have a test that can diagnose Covid, the pathological condition not the virus, remotely.

Incorporated within Dx with the other respiratory conditions that should prove an enormous money-spinner for RAP. From all the statements made so far the BOD, with its scientific advisers, believe that it is only a matter of time before the 'twigging' with be effective.

What other method is going to allow that?

What other company has the necessary data base of sound signals produced prior to Covid emerging?

What other company has already a suite of approved and registered tests that can distinguish the other respiratory conditions and can then be in a position to ad Covid to that suite.

The ResAppDx value has been enormously understated in my opinion. As well as the Covid diagnosis referred to above all the other factors outlined in the link below need to be taken into account.

poorinvestor

https://hotcopper.com.au/threads/valuing-resapp-health.6736339/page-439?post_id=63060062